Farrow Jeffrey S 4

What Happened

• Jeffrey S. Farrow, Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals (TARS), had 13,042 Restricted Stock Units (RSUs settle into shares) convert to common stock on March 15, 2026. The Form 4 shows 13,042 shares acquired through conversion (transaction code M).
• The filing also shows two dispositions of 8,020 and 5,022 shares (both at $0), which equal the 13,042 shares issued—these appear to be withholding to satisfy tax obligations. No cash proceeds are reported from the dispositions.

Key Details

• Transaction date: 2026-03-15 (reported on Form 4 filed 2026-03-17). Transaction code: M (exercise/conversion of derivative/RSU settlement).
• Acquired: 13,042 shares (settlement of vested RSUs); Disposed/withheld: 8,020 and 5,022 shares at $0. Total shares withheld = 13,042.
• Price/Value: No cash purchase or sale price reported; the disposals are reported at $0, indicating tax withholding rather than a market sale.
• Shares owned after transaction: not specified in the filing.
• Footnotes: RSUs represent a contingent right to one share (F1–F2). RSUs originated from grants on March 7, 2024 (vesting 25% each Mar 15 of 2025–2028) and March 5, 2025 (vesting 25% each Mar 15 of 2026–2029) under the 2020 Stock Plan (F3–F4).
• Filing timeliness: Reported promptly (transaction 3/15/2026; Form 4 filed 3/17/2026).

Context

• This was an RSU settlement with shares withheld for taxes—a common payroll/tax event that does not represent an open-market sale or purchase by the insider. It does not, by itself, indicate a change in insider sentiment about the company.